BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35070976)

  • 1. Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists.
    Fernández O; Lázaro-Quintela M; Crespo G; Soto de Prado D; Pinto Á; Basterretxea L; Gómez de Liaño A; Etxaniz O; Blasco S; Gabás-Rivera C; Aceituno S; Palomar V; Polanco-Sánchez C
    Front Oncol; 2021; 11():773366. PubMed ID: 35070976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Do Treatment Preferences of Patients With Cancer Compare With Those of Oncologists and Family Members? Evidence From a Discrete Choice Experiment in China.
    Zhang M; He X; Wu J; Wang X; Jiang Q; Xie F
    Value Health; 2022 Oct; 25(10):1768-1777. PubMed ID: 35710892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists' and Urologists' Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries.
    Panattoni L; Kearney M; Land N; Flottemesch T; Sullivan P; Kirker M; Bharmal M; Hauber B
    Pharmacoeconomics; 2024 Mar; ():. PubMed ID: 38472738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study.
    Boqué C; Abad MR; Agustín MJ; García-Goñi M; Moreno C; Gabás-Rivera C; Granados E; Castro-Gómez A; Pardo C; Lizán L
    J Geriatr Oncol; 2020 Jan; 11(1):24-30. PubMed ID: 30954406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
    Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Shinde R; Basurto E; Joseph RW
    Patient Prefer Adherence; 2017; 11():1389-1399. PubMed ID: 28860722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient versus physician preferences for lipid-lowering drug therapy: A discrete choice experiment.
    Zhang L; Chen J; Cao Z; Zhang M; Ma R; Zhang P; Yao G; Li X
    Health Expect; 2024 Apr; 27(2):e14043. PubMed ID: 38590082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
    Thomas C; Ailawadhi S; Popat R; Kleinman D; Ross MM; Gorsh B; Mulnick S; O'Neill A; Paka P; Hanna M; Krucien N; Molinari A; Gelhorn HL; Perera S
    Front Med (Lausanne); 2023; 10():1271657. PubMed ID: 38076274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis.
    Díaz-Torné C; Urruticoechea-Arana A; Ivorra-Cortés J; Díaz S; Dilla T; Sacristán JA; Inciarte-Mundo J; Comellas M; Prades M; Lizán L
    Adv Ther; 2020 Apr; 37(4):1479-1495. PubMed ID: 32088860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients.
    Grivas P; Veeranki P; Chiu K; Pawar V; Chang J; Bharmal M
    Future Oncol; 2023 Feb; 19(5):369-383. PubMed ID: 36876486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China.
    Sun H; Wang H; Xu N; Li J; Shi J; Zhou N; Ni M; Hu X; Chen Y
    Patient Prefer Adherence; 2019; 13():1701-1709. PubMed ID: 31631985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
    Stone RL; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Ritz S; Mulvihill E; Monberg M; Szamreta EA; Amin S; McLaurin K
    Future Oncol; 2022 Feb; 18(4):491-503. PubMed ID: 34875854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferences and Willingness to Pay for Medication in Patients with Renal Cell Carcinoma in China: A Discrete-Choice Experiment.
    Ding R; Shao R; Zhang L; Yan J
    Patient; 2024 Jan; 17(1):97-108. PubMed ID: 38030868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Societal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain.
    Martinón-Torres F; de Miguel ÁG; Ruiz-Contreras J; Vallejo-Aparicio LA; García A; Gonzalez-Inchausti MC; de Gomensoro E; Kocaata Z; Gabás-Rivera C; Comellas M; Prades M; Lizán L
    Infect Dis Ther; 2023 Jan; 12(1):157-175. PubMed ID: 36367677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment.
    Beusterien K; Maculaitis MC; Hallissey B; Gaschler MM; Smith ML; Law EH
    Patient Prefer Adherence; 2021; 15():611-623. PubMed ID: 33776424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parental preferences for the procedural sedation of children in dentistry: a discrete choice experiment.
    Zhuge J; Zheng D; Li X; Nie X; Liu J; Liu R
    Front Pediatr; 2023; 11():1132413. PubMed ID: 38116578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.
    Maculaitis MC; Liu X; Will O; Hanson M; McRoy L; Berk A; Crastnopol M
    Patient Prefer Adherence; 2020; 14():2201-2214. PubMed ID: 33177814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment.
    González JM; Ogale S; Morlock R; Posner J; Hauber B; Sommer N; Grothey A
    Cancer Manag Res; 2017; 9():149-158. PubMed ID: 28490902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment.
    Yin Y; Peng Q; Ma L; Dong Y; Sun Y; Xu S; Ding N; Liu X; Zhao M; Tang Y; Mei Z; Shao H; Yan D; Tang W
    Qual Life Res; 2024 Mar; 33(3):753-765. PubMed ID: 38079024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives.
    Oliveri S; Lanzoni L; Veldwijk J; de Wit GA; Petrocchi S; Janssens R; Schoefs E; Smith MY; Smith I; Nackaerts K; Vandevelde M; Louis E; Decaluwé H; De Leyn P; Declerck H; Petrella F; Casiraghi M; Galli G; Garassino MC; Girvalaki C; Huys I; Pravettoni G
    Front Psychol; 2023; 14():1062830. PubMed ID: 37425173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Study of Patient Preferences for the Treatment of Non-small Cell Lung Cancer in Western China: A Discrete-Choice Experiment.
    Liu F; Hu H; Wang J; Chen Y; Hui S; Hu M
    Front Public Health; 2021; 9():653450. PubMed ID: 33842426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.